Shots:
The US FDA has approved Rhapsido for the treatment of adults with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. Regulatory filings are also made in the EU, Japan & China, with priority review granted in China
Approval was backed by P-III (REMIX-1 & 2) trials in CSU, which showed improved…
